Drugs / Mefloquine Artesunate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01082718 | Mar → Oct 2010 | malaria | Centers for Disease Control and Prevention | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00701961 | Oct 2008 → Jul 2009 | Plasmodium falciparum malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01107145 | Feb 2011 → Jan 2012 | Plasmodium vivax malaria | Centers for Disease Control and Prevention | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mefloquine-artesunate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00701961 ↗ |
| Route | Oral | “Treatment was a fixed-dose combination of oral artesunate and mefloquine once daily for three days.” PMID 32025570 ↗ Mar 2019 |